TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Agreement between filtered plasma and postfilter iCa values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bedside clotting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess mortality from cardiac causes
Endpoint domain: Mortality/survival
Primary endpoint: postoperative wound complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of correct answers to questions regarding surgical risk and extent of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mucociliary clearance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death after discharge from HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Defaecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Daily basal insulin dose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient preference for s.c. over i.v. trastuzumab
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Clinician-reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: percent change in maximal vessel wall thickness of atherosclerotic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Degrees of forward elevation of shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total lens events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Nuclear events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: PSC events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean corpuscular hemoglobin concentration (MCHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red cell distribution width index (RDW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lymphocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Dilatation of the cervix after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of partial expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance (digestive disorders, pelvic pain, metrorrhagia)
Endpoint domain: Adverse events/effects
Primary endpoint: vascular function (flow-mediated vasodilation and pulse wave velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver mean MRI-PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anger-Hostility subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: A1GP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute bioavailability of oral DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute bioavailability of oral ARTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of oral DHA to oral ARTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student satisfaction with performance feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: student evaluation of tutors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean OSCE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hot flush frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arthritis pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: House-Brackmann-Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (FaCE scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: emotional depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nonresponse to opioid therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Risk for confusion
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of ischaemic cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oswestry Disability Index score reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dallas Pain Questionnaire score reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Back pain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of TOS and SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of MDA in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration of niflumic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the curve from zero to infinity (AUC(inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multivitamin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydrorrhea or discharge amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and cramping duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h total morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain score at rest and on knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbicidal activity of leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Continence achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sling erosions requiring removal
Endpoint domain: Adverse events/effects
Primary endpoint: absolute BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itching reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in speaking behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in child anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of vomiting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to CHD death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in motor performance of the deep cervical flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per child screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hgb(A1C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fructosamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal uroflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness of pelvic floor muscle training in treating stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lymphadenopathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: levels of cancer worries
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stricture rate following anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptomatic relief after dilation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: production of proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean weight reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak blood glucose concentration after a standard test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean glycosylated haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean global QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: COSS-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: success rate of BTX-A injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient convenience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of gall bladder motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of LDLP cholesterol content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum proportion of 20:4n-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of urinary excretion 11-dehydro TXB2 to 6-keto PGF 1alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vmean values of the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: AMPPro scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPnoro scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of resected lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-booster local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Immune responses (CP5, CP8, ClfA titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Capacity for fixation suppression of the vestibulo-ocular reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional CBF in the cerebrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peroxynitrite inhibitory activity in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall SLAM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the size of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to CD4+ T cell count ≤350 cells/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confidence and knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protective immune response (anti-HBs >or=10 IU/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: log(10)DRS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of opioid-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to pay (WTP) for cataract surgeries
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Drinks Meter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harms
Endpoint domain: Adverse events/effects
Primary endpoint: Total nasal symptom score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Depression Rating Scale‐Revised scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IgG anti-OspA geometric mean titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of local injection site reactions and general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: mean reduction in log‐transformed AAA volume growth rate (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse symptoms after IV contrast agent administration
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with educational process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: restoration of the joint line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endurance time to constant work-rate exercise after bronchodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function (peak expiratory flow rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in 0-24 h wmFEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decreases in suicidality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreases in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in social adjustment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: CVD risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean visual loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity (VA) > or = 0.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean SSDE reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of immediate breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of thermal care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of clean delivery kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of active variceal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re‐bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Junctional varix obliteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procoagulant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sustained abstinence at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KSS and WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WheelCon-M scores
Endpoint domain: Life impact
Endpoint subdomain: Confidence
Primary endpoint: incidence of ischemic/thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean AUA symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First metatarsal length shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal discrepancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of alanine transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of aspartate transaminase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weight of newborn baby
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ischemic burden assessed by ST-segment shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to eyes opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to command response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to suitability for discharge from recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with HELP-COPD intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Meningococcal serum bactericidal assay (SBA) titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody concentration ≥0.35μg/mL after dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bacterial plaque removal effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregivers' feelings of preparedness and support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: barriers to implementing IDTs
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: facial pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior nasal discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of pain after fistulectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Objective failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Contact lens tolerance prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with rehabilitation services
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Manic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of inadequacy of micronutrient intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total Protein Concentration (TPC) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: validated smoking cessation at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% improvement in PASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of tramadol ODT for PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose of thiopental for immobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose of propofol for immobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nights with nightmares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nightmares per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nightmare severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Line angles in Steiner cephalometric analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of overall and individual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of PTSD symptoms in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with reference glucose analyser
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Home OGTT device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Home OGTT device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac power output at peak workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VO₂
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: V E/VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of bacterial colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes